Arrowhead Reaches $673.5 Million Deal with Amgen in Cardiovascular Risk Factors
Amgen signed two license agreements to commercialize Arrowhead Pharmaceuticals’ RNA interference therapies for cardiovascular disease.
Amgen received a worldwide, exclusive license to market Arrowhead’s RNAi ARC-LPA program, designed to reduce elevated lipoprotein(a), a risk factor for atherosclerotic cardiovascular disease. Amgen also received an option to license an RNAi therapy for an undisclosed cardiovascular target, and will be fully responsible for clinical development and commercialization.
Arrowhead will receive $35 million in upfront payments, $21.5 million in equity investments by Amgen in Arrowhead common stock, and up to $617 million in option payments, and development, regulatory and sales milestone payments.